Industry News
CLDN18.2-Targeted ADCs: A Promising Break…
As of 2025, the global R&D landscape for CLDN18.2-targeted antibody-drug conjugates (ADCs) is expanding rapidly, with multiple candidates entering mid- to late-stage clinical trials.
Aficamten: Novel Cardiac Myosin Inhibitor…
Aficamten is an investigational, oral, small molecule cardiac myosin inhibitor. It was designed to reduce the hypercontractility associated with Hypertrophic cardiomyopathy (HCM)
HER2 ADCs 2025: Complete Guide to Approve…
To date, there are 19 ADCs approved worldwide. Among them, four HER2-targeting ADCs have received regulatory approval worldwide.
Comprehensive Overview of Common Chemical…
Discover a comprehensive guide to common sunscreen ingredients, their UV protection ranges, stability, safety, and regulatory approvals.
Vepdegestrant NDA Accepted: A Milestone f…
On August 8, 2025, Arvinas and Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for vepdegestrant (ARV-471).
FDA Approves 16 Innovative Drugs in H1 20…
In H1 2025, the FDA approved 16 innovative drugs, including breakthroughs in antibody-drug conjugates (ADCs) and novel treatments for cancer, pain, infections, and rare diseases.
Next-Generation ADC: How Bispecific ADCs …
On July 3, 2025, Biokin Pharma, a leading biopharma company based in China, announced that its proprietary bispecific ADC iza-bren (izalontamab brengitecan, BL-B01D1) met the primary endpoint…
AACR 2025 Highlights: Dual Payload & …
Discover key highlights from the 2025 AACR Annual Meeting, where cutting-edge ADC innovations—from dual-payloads to immunotherapy combos—are reshaping cancer treatment.
N-Benzylhydroxylamine Hydrochloride (CAS …
N-Benzylhydroxylamine hydrochloride (CAS 29601-98-7) is a versatile organic compound featuring a unique nitrogen–oxygen (N–O) functional group. This structural characteristic endows it with…
The Next Generation of Obesity Treatments…
Recently, Nature published an in-depth report on the upcoming wave of next-generation weight-loss therapies.
sales@huatengusa.com
+86 0731 89916275